As one of only a select number of pediatric hospitals in the U.S., Texas Children’s Cancer Center will now offer I-131 MIBG, a targeted nuclear medicine therapy that combines metaiodobenzylguanidine (MIBG) with radioactive iodine (I-131) to treat patients with high-risk neuroblastoma. This is the first pediatric treatment location in Houston designed specifically for this therapy and one of only a handful in the southern U.S. For more information about MIBG therapy at Texas Children’s Cancer Center, visit […]
